Immunopathology of polymyalgia rheumatica: Links to clinical manifestations and prospects for targeted therapy
Open Access
- 14 September 2026
- journal article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 189-201
Abstract
Polymyalgia rheumatica (PMR) is one of the most common inflammatory rheumatic diseases affecting older adults. The aim of this review was to analyze current concepts of the immunopathogenesis of PMR and the possibilities of pathogenetic therapy for this disease. A literature search was conducted in the PubMed, Scopus, Web of Science, eLIBRARY.RU and Google Scholar databases using the following keywords: “polymyalgia rheumatica”, “immunopathogenesis”, “immunosenescence”, “methotrexate”, “biologic therapy”, “IL-6 inhibitors”, “IL-17 inhibitors”, “targeted therapy”, “tocilizumab”, “sarilumab”, “olokizumab”, “tofacitinib”, “baricitinib”, and their Russian-language equivalents. A total of 110 publications were initially identified. Following full-text assessment, 24 articles were excluded due to lack of relevance to the review topic, insufficient informativeness, or the absence of significant data regarding the immunopathogenesis and treatment of PMR. A total of 86 publications were included in the qualitative analysis, comprising randomized controlled trials, cohort studies, clinical observations, systematic reviews, and basic research studies. Twelve publications focusing on the immunopathology of PMR were used for preparation of the Introduction section. The analysis demonstrated that immunosenescence, activation of innate and adaptive immunity, disturbances in Tand B-cell immune responses, and dysregulation of the cytokine network, with a central role of interleukin-6, are key contributors to the pathogenesis of PMR. The most convincing evidence currently supports the use of interleukin-6 and interleukin-17 inhibitors, whose efficacy has been confirmed in randomized clinical trials. Expanding knowledge of the mechanisms underlying the disease contributes to the development of personalized treatment approaches for patients with PMR and to the optimization of long-term disease control.Keywords
This publication has 79 references indexed in Scilit:
- Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid TherapyJAMA, 2022
- JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapyJournal of Leukocyte Biology, 2019
- Methotrexate Restores Regulatory T Cell Function Through Demethylation of the FoxP3 Upstream Enhancer in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2015
- Disturbed B Cell Homeostasis in Newly Diagnosed Giant Cell Arteritis and Polymyalgia RheumaticaArthritis & Rheumatology, 2014
- Methotrexate increases expression of cell cycle checkpoint genes via JNK activationArthritis & Rheumatism, 2011
- Increased sensitivity to apoptosis induced by methotrexate is mediated by JNKArthritis & Rheumatism, 2011
- Serum interleukin‐6 receptor in polymyalgia rheumatica: A potential marker of relapse/recurrence riskArthritis Care & Research, 2008
- Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphismsArthritis & Rheumatism, 2000
- Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: Evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritisArthritis & Rheumatism, 2000
- Correlation of interleukin‐6 production and disease activity in polymyalgia rheumatica and giant cell arteritisArthritis & Rheumatism, 1993